The return on investment is low, and many large pharmaceutical companies have abandoned the field. According to the authors, collaboration and risk-sharing can help keep companies in anti-infective ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

With the signing of the OTA, initial BARDA funds of USD 29 million have been committed to support the development of the antifungals fosmanogepix and BAL2062. BARDA’s financial contribution is assumed ...

A new nationwide Danish study published in The Lancet Psychiatry found that individuals with schizophrenia spectrum disorders ...

A new Lancet study forecast what may happen over the next 25 years if more isn't done to address antimicrobial resistant ...